Corbus begins dosing in Phase II trial of Resunab to treat dermatomyositis
Resunab is a new synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. The company noted that CB2 activation triggers
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Under the agreement, EyeGate will receive an upfront cash payment, development-based milestone payments related to the completion of development for the indication of anterior uveitis and an approval-based